Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting

Verdict

Headline takes no side. We score TERN +1.00 — strongly bullish.

Headline says

No call

No rating or direction in the headline

Expected · TERN

+1.00strongly bullish

−1 bearish0bullish +1

More positive than 98% of ticker scores this week